• Je něco špatně v tomto záznamu ?

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

P. Sonneveld, A. Chanan-Khan, K. Weisel, AK. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, MV. Mateos, TM. Mark, MD. Levin, T. Ahmadi, X. Qin, W. Garvin Mayo, X. Gai, J. Carey, R. Carson, A. Spencer

. 2023 ; 41 (8) : 1600-1609. [pub] 20221122

Jazyk angličtina Země Spojené státy americké

Typ dokumentu randomizované kontrolované studie, multicentrická studie, klinické zkoušky, fáze III, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23003842

PURPOSE: At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus bortezomib and dexamethasone (Vd) alone in relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the final analysis for overall survival (OS). METHODS: CASTOR was a multicenter, randomized, open-label, phase III study during which eligible patients with ≥ 1 line of prior therapy were randomly assigned to Vd (up to eight cycles) with or without daratumumab (until disease progression). After positive primary analysis and protocol amendment, patients receiving Vd were offered daratumumab monotherapy after disease progression. RESULTS: At a median (range) follow-up of 72.6 months (0.0-79.8), significant OS benefit was observed with D-Vd (hazard ratio, 0.74; 95% CI, 0.59 to 0.92; P = .0075). Median OS was 49.6 months with D-Vd versus 38.5 months with Vd. Prespecified subgroup analyses demonstrated an OS advantage with D-Vd versus Vd for most subgroups, including patients age ≥ 65 years and patients with one or two prior lines of therapy, International Staging System stage III disease, high-risk cytogenetic abnormalities, and prior bortezomib treatment. The most common (≥ 10%) grade 3/4 treatment-emergent adverse events with D-Vd versus Vd were thrombocytopenia (46.1% v 32.9%), anemia (16.0% v 16.0%), neutropenia (13.6% v 4.6%), lymphopenia (10.3% v 2.5%), and pneumonia (10.7% v 10.1%). CONCLUSION: D-Vd significantly prolonged OS in patients with RRMM, with the greatest OS benefit observed in patients with one prior line of therapy. To our knowledge, our results, together with the OS benefit observed with daratumumab plus lenalidomide and dexamethasone in the phase III POLLUX study, demonstrate for the first time an OS benefit with daratumumab-containing regimens in RRMM (ClinicalTrials.gov identifier: NCT02136134 [CASTOR]).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003842
003      
CZ-PrNML
005      
20230425140920.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.21.02734 $2 doi
035    __
$a (PubMed)36413710
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sonneveld, Pieter $u Erasmus MC Cancer Institute, Rotterdam, the Netherlands $1 https://orcid.org/0000000208082237
245    10
$a Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial / $c P. Sonneveld, A. Chanan-Khan, K. Weisel, AK. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, MV. Mateos, TM. Mark, MD. Levin, T. Ahmadi, X. Qin, W. Garvin Mayo, X. Gai, J. Carey, R. Carson, A. Spencer
520    9_
$a PURPOSE: At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus bortezomib and dexamethasone (Vd) alone in relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the final analysis for overall survival (OS). METHODS: CASTOR was a multicenter, randomized, open-label, phase III study during which eligible patients with ≥ 1 line of prior therapy were randomly assigned to Vd (up to eight cycles) with or without daratumumab (until disease progression). After positive primary analysis and protocol amendment, patients receiving Vd were offered daratumumab monotherapy after disease progression. RESULTS: At a median (range) follow-up of 72.6 months (0.0-79.8), significant OS benefit was observed with D-Vd (hazard ratio, 0.74; 95% CI, 0.59 to 0.92; P = .0075). Median OS was 49.6 months with D-Vd versus 38.5 months with Vd. Prespecified subgroup analyses demonstrated an OS advantage with D-Vd versus Vd for most subgroups, including patients age ≥ 65 years and patients with one or two prior lines of therapy, International Staging System stage III disease, high-risk cytogenetic abnormalities, and prior bortezomib treatment. The most common (≥ 10%) grade 3/4 treatment-emergent adverse events with D-Vd versus Vd were thrombocytopenia (46.1% v 32.9%), anemia (16.0% v 16.0%), neutropenia (13.6% v 4.6%), lymphopenia (10.3% v 2.5%), and pneumonia (10.7% v 10.1%). CONCLUSION: D-Vd significantly prolonged OS in patients with RRMM, with the greatest OS benefit observed in patients with one prior line of therapy. To our knowledge, our results, together with the OS benefit observed with daratumumab plus lenalidomide and dexamethasone in the phase III POLLUX study, demonstrate for the first time an OS benefit with daratumumab-containing regimens in RRMM (ClinicalTrials.gov identifier: NCT02136134 [CASTOR]).
650    _2
$a lidé $7 D006801
650    _2
$a senioři $7 D000368
650    12
$a mnohočetný myelom $x farmakoterapie $7 D009101
650    _2
$a bortezomib $x škodlivé účinky $7 D000069286
650    12
$a neutropenie $7 D009503
650    _2
$a progrese nemoci $7 D018450
650    _2
$a dexamethason $x škodlivé účinky $7 D003907
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Chanan-Khan, Asher $u Mayo Clinic Florida, Jacksonville, FL
700    1_
$a Weisel, Katja $u Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Nooka, Ajay K $u Winship Cancer Institute, Emory University, Atlanta, GA $1 https://orcid.org/0000000341656869
700    1_
$a Masszi, Tamas $u Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary $1 https://orcid.org/0000000323229863
700    1_
$a Beksac, Meral $u Ankara University, Ankara, Turkey $1 https://orcid.org/0000000317978657
700    1_
$a Spicka, Ivan $u 1st Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic
700    1_
$a Hungria, Vania $u Clínica Médica São Germano, São Paulo, Brazil $1 https://orcid.org/0000000243271957
700    1_
$a Munder, Markus $u Third Department of Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany $1 https://orcid.org/0000000349478796
700    1_
$a Mateos, Maria-Victoria $u University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain $1 https://orcid.org/0000000323901218
700    1_
$a Mark, Tomer M $u Department of Medicine, University of Colorado, Aurora, CO $1 https://orcid.org/0000000169960497
700    1_
$a Levin, Mark-David $u Albert Schweitzer Hospital, Dordrecht, the Netherlands $1 https://orcid.org/0000000321393547
700    1_
$a Ahmadi, Tahamtan $u Genmab US Inc, Plainsboro, NJ
700    1_
$a Qin, Xiang $u Janssen Research & Development, LLC, Spring House, PA
700    1_
$a Garvin Mayo, Wendy $u Janssen Research & Development, LLC, Raritan, NJ
700    1_
$a Gai, Xue $u Janssen Research & Development, LLC, Beijing, China $1 https://orcid.org/0000000347740607
700    1_
$a Carey, Jodi $u Janssen Research & Development, LLC, Spring House, PA
700    1_
$a Carson, Robin $u Janssen Research & Development, LLC, Spring House, PA
700    1_
$a Spencer, Andrew $u Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia $1 https://orcid.org/0000000205317424
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 41, č. 8 (2023), s. 1600-1609
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36413710 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140917 $b ABA008
999    __
$a ok $b bmc $g 1924486 $s 1190051
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 41 $c 8 $d 1600-1609 $e 20221122 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace